Skip to content

Psilocybin: all studies

Page 220 of 439: studies 2,191 to 2,200 of 4,389, newest first. Back to the psilocybin overview

Research

The Intersection of Mental Health and Sexual and Gender Minority Identities for Older Adults Living with Human Immunodeficiency Virus: A Narrative Review.

The Nursing clinics of North America June 1, 2024 David Agor, Brandon A Knettel, Kenneth Daici et al. 2 citations

The transition of HIV into a chronic illness has brought to the forefront the pressing need to address the complex web of social determinants of HIV outcomes. A structured literature search and narrative review of studies describing intervention strategies for mental health among sexual/gender minority (SGM) older adults living with HIV (OALWH) published in the last decade identified 2 studies...

Not all serotonergic psychedelics are alike - they induce distinct patterns of altered metabolic activity and connectivity

May 28, 2024 Frederik Gudmundsen, Julia Czurylo, Camilla Trang Vo et al. 1 citation preprint

Serotonergic psychedelic drugs have shown promising benefits in trials for various neuropsychiatric disorders. While the acute effects of these psychedelics last only a few hours, the positive therapeutic effects can persist long after a single administration. Serotonergic psychedelics produce their psychedelic effects by activating serotonin 2A receptors, but they differ in other...

On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.

May 23, 2024 Daniël Hoyer

There is controversy about a causal role of serotonin (5-HT) in depression, some arguing that there is no proof for impaired brain 5-HT function in depressed patients. Major depressive disorder comes with multiple endophenotypes; not surprisingly classical antidepressants (tricyclics, MAO inhibitors, SSRIs, SNRIs) are not universally effective. Most antidepressants target the 5-HT system,...

Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder

International Review of Psychiatry May 23, 2024 Rebecca Ehrenkranz, Manish Agrawal, J. Kim Penberthy et al. 5 citations

Prolonged Grief Disorder (PGD) is distinct from yet related to non-pathologic grief, depression, addiction, and Post-Traumatic Stress Disorder (PTSD) with a prevalence of up to 10% in bereaved populations. Hallmarks of PGD include functional impairment a year or more post-bereavement and intense yearning for the deceased. Current treatments for PGD are typically psychological rather than...

Is it now time to prepare psychiatry for a psychedelic future?

The British Journal of Psychiatry May 20, 2024 David Nutt, Ilana B Crome, Allan H. Young 18 citations

Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these...

Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens

Psychiatry and Clinical Neurosciences Reports May 16, 2024 Shunichiro Ikeda, Toshihiko Kinoshita

During the 1960s, several studies were conducted to test the therapeutic effects of hallucinogenic drugs, also known as psychedelics, on various disorders, such as major depressive disorder (MDD). However, the non-medical use of these substances became rampant due to their hallucinogenic effects, leading to their classification as narcotics in numerous countries by the 1970s. Since the 1990s,...

DOI: 10.1002/pcn5.196 (opens in new tab) Psilocybin The renaissance Hallucinogen Focus optics +1

Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.

Psychopharmacology May 14, 2024 Mazen A Atiq, Matthew R Baker, Jennifer L. Vande Voort et al. 12 citations

Recent research with classic psychedelics suggests significant therapeutic potential, particularly for neuropsychiatric disorders. A mediating influence behind symptom resolution is thought to be the personal insight - at times, bordering on the mystical - one acquires during the acute phase of a psychedelic session. Indeed, current clinical trials have found strong correlations between the...

Advancements in Psychoactive Alkaloid Delivery, Neuroenhancement, and Psychedelic Therapies: Exploring the Frontiers of Modern Pharmacology

ACS Medicinal Chemistry Letters May 8, 2024 Robert B. Kargbo 2 citations

This Patent Highlight explores advancements in pharmacology, focusing on the novel delivery and application of psychoactive substances. It highlights the development of transdermal formulations for psychoactive alkaloids, neuroenhancement techniques to augment emotional responses, and the intravenous infusion of psilocybin or psilocin for various therapeutic purposes. Additionally, it delves...

DOI: 10.1021/acsmedchemlett.4c00181 (opens in new tab) Psilocybin Transdermal Pharmacology Neurostimulation +2

Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study

Journal of Psychoactive Drugs May 7, 2024 Sandeep M. Nayak, Sydney H White, Samantha Hilbert et al. 18 citations

Recent studies suggest psychedelic use may be associated with changes in a variety of beliefs or belief-like states, including increased 1) mind perception, 2) non-naturalistic beliefs, and 3) Atheist-Believer status (e.g. believer, agnostic, or nonbeliever). We conducted a prospective longitudinal study among participants (N = 657) who planned to have a psilocybin experience outside a...

Suspension of Short‐lasting, Unilateral, Neuralgiform headache attacks with Conjunctival injection and Tearing (SUNCT) symptoms with ayahuasca and serotonergic psychedelics

Headache: The Journal of Head and Face Pain May 1, 2024 Jonathan A. Leighton, Cyril Petignat, Brian E. Mcgeeney 2 citations

Plain Language Summary A suicidal patient with Short‐lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing (SUNCT) whose excruciating condition did not respond to various treatments discovered that ayahuasca, a psychoactive concoction used by indigenous populations of South America, caused his attacks to cease entirely. Inhaled N , N ‐dimethyltryptamine (DMT),...